Browse the evidence

Achieving early weight-loss success (≥5% loss at 6 months) significantly increases the odds of long-term retention, while early weight-loss failure (≥0% change at 1 month) significantly decreases it.

If you don't see weight loss in the first month, you are at high risk of dropping out. Programs should identify these individuals early and provide extra support to help them get back on track, as early failure is a strong predictor of quitting.

Consuming whey protein, which has high leucine density, stimulates muscle protein synthesis more effectively than proteins with lower leucine content (such as wheat, soy, or casein) by triggering the mTORC1 signaling pathway.

Choose whey protein for your post-workout or high-priority meals because its high leucine content triggers muscle building signals more effectively than plant proteins or casein. Ensure you are also doing resistance training to maximize these benefits.

Consuming whey protein in combination with resistance training results in greater increases in muscle mass compared to resistance training alone or isonitrogenous casein intake.

If you are lifting weights, add whey protein to your diet. A study showed that taking 120g of whey daily (split into 4 servings) alongside resistance training led to 5 times more muscle growth than taking the same amount of nitrogen from casein.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce clinically significant weight loss (15-21%) and improve comorbidities, but require long-term continuous use to maintain benefits.

GLP-1 medications like semaglutide and tirzepatide are highly effective for significant weight loss (15-21%) and improving health conditions like diabetes and heart disease. However, they are not cosmetic shortcuts. You must commit to long-term use, as stopping the medication usually leads to regaining the weight. Work with your doctor to manage side effects and adjust other medications as you lose weight.

GLP-1/GIP dual receptor agonists (e.g., tirzepatide) produce significantly greater weight loss than GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and non-GLP-1 agents (e.g., orlistat, phentermine/topiramate) in weight management trials.

If you are struggling with obesity, GLP-1/GIP dual agonists like tirzepatide are currently the most effective pharmacological option for weight loss, significantly outperforming older medications and even single-target GLP-1 agonists. This comes with the need for weekly injections (or oral alternatives) and careful dose escalation to manage side effects.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly) and dual incretin agonists (tirzepatide) significantly reduce hepatic steatosis and improve or resolve steatohepatitis (MASH) in patients with MASLD, primarily through sustained weight loss and improved insulin sensitivity.

If you have fatty liver disease linked to metabolic issues, GLP-1 medications like semaglutide are currently the most effective pharmacological tool to reverse liver inflammation and fat. They work by targeting the root metabolic causes rather than just the liver itself. Consult a doctor to see if you qualify for these treatments, especially if lifestyle changes alone haven't resolved your liver health markers.

Intensive lifestyle interventions (dietary restriction and exercise) can induce type 2 diabetes remission, with remission rates strongly dose-dependent on the magnitude of weight loss, particularly when exceeding 15 kg.

To achieve type 2 diabetes remission, you must lose a significant amount of weight, ideally 15 kg or more, through a combination of calorie-restricted diet and regular exercise (at least 150 minutes/week). This is not just about weight loss; it requires a multidisciplinary support system including dietitians and psychological counseling to manage the mental burden of strict lifestyle changes. Shorter diabetes duration and higher BMI (27-45) predict better success.

A worksite-based behavioral intervention emphasizing hunger and craving management via diet composition produces significant, sustained weight loss (approx. 9%) and improvements in cardiometabolic risk factors (glucose, triglycerides) over 18 months, regardless of whether meal replacements are used.

Adopt a behavioral program that focuses on managing hunger and cravings through diet composition rather than just calorie counting. This approach can lead to significant, sustained weight loss (around 9%) and improved heart health markers over 18 months. You do not necessarily need meal replacements to lose weight, though they may help lower cholesterol further. The key is a low-burden, sustainable behavioral change.

Tirzepatide, a dual GLP-1/GIP receptor agonist, provides greater HbA1c reduction and weight loss compared to semaglutide 1 mg in patients with Type 2 Diabetes.

If you need significant weight loss and blood sugar control, ask your doctor about tirzepatide. It may work better than older GLP-1 drugs like semaglutide 1 mg, but it is more expensive.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (10-21%) but also reduce lean body mass, necessitating resistance training to preserve muscle and performance in physically active individuals.

If you are using GLP-1 agonists like semaglutide or tirzepatide for weight loss, expect to lose both fat and some muscle. To protect your strength and athletic performance, you must incorporate resistance training into your routine. This combination helps offset the lean mass loss associated with these drugs. Do not rely on the medication alone; long-term maintenance requires continuous therapy and lifestyle adherence, as stopping treatment typically leads to weight regain.

Semaglutide (2.4 mg) is the most cost-effective and clinically effective pharmacological intervention for obesity treatment compared to other FDA-approved medications and lifestyle interventions.

For adults with obesity, Semaglutide (2.4 mg weekly) combined with diet and exercise is currently the most effective and economically favorable medication option available, outperforming older drugs like Orlistat in most healthcare settings.

Multidisciplinary therapy combining nutritional, physical, and behavioral interventions reduces body weight, fat mass, and cardiometabolic risk factors in adults with obesity.

To manage obesity effectively, you need a team approach that includes diet, exercise, and behavioral counseling, rather than just one of these. Aim for sessions 2-3 times a week, lasting at least 20 minutes, over a period of weeks to months. This combined approach helps reduce weight and fat while preserving muscle and improving metabolic health, which is crucial for long-term success.

Phenotype-guided treatment selection (matching drug mechanism to obesity subtype like 'hungry brain' or 'slow burn') results in significantly greater weight loss compared to standard care.

Ask your doctor about your obesity phenotype (e.g., 'hungry brain', 'slow burn'). Matching your medication to your specific metabolic or behavioral drivers can nearly double your weight loss success compared to standard treatment approaches.

Aerobic and resistance exercise reduce hepatic steatosis and improve insulin sensitivity in MASLD patients independently of significant body weight loss.

You do not need to lose weight to improve your liver health through exercise. Both aerobic exercise (45-60 minutes, 3-5 times a week) and resistance training (3 times a week for 8-12 weeks) can significantly reduce liver fat and improve insulin sensitivity, even if your body weight remains stable. Focus on consistency and metabolic health rather than just the number on the scale.

Tirzepatide (TZP) produces significantly greater weight loss than semaglutide (SEM) in patients with rheumatic and musculoskeletal diseases (RMDs), with TZP users losing 8.2% of body weight compared to 5.8% for SEM users at 12 months.

If you have a rheumatic condition and are using GLP-1 medications, Tirzepatide is associated with greater weight loss than Semaglutide. In this large study, Tirzepatide users lost 8.2% of their body weight at 12 months, compared to 5.8% for Semaglutide users. This benefit was observed even in patients with mobility limitations, suggesting that pharmacological intervention can overcome some barriers to weight loss in this population.

High-intensity resistance exercise (RE) is the primary non-pharmacological intervention for preventing and treating osteosarcopenia, as it simultaneously increases lean body mass, strength, and bone mineral density (BMD), whereas daily activities and cardiovascular exercises are insufficient for stimulating osteoblastogenesis.

To fight osteosarcopenia, you must lift heavy weights. Walking and swimming are healthy but will not build bone density. Focus on high-intensity resistance exercises, ideally combined with adequate protein, creatine, and vitamin D intake. Consult a professional to ensure safety, especially if you have existing bone fragility.

The effectiveness of protein supplementation on lean mass and strength is significantly higher in sarcopenic and frail older adults compared to overweight or obese older adults.

If you are an older adult who is frail, sarcopenic, or institutionalized, adding protein supplements to your resistance training is more likely to help you build lean mass and strength. If you are overweight or obese, you may not see these benefits, as your body's response to protein may be blunted by excess weight and lower activity levels.

Resistance exercise training (RET) volume is the primary driver of skeletal muscle hypertrophy, with higher weekly volumes yielding greater muscle growth up to a specific threshold.

To maximize muscle growth, focus on increasing your total training volume (sets x reps x weight) over time. You do not need to lift extremely heavy weights; moderate loads work just as well if you train close to failure. However, be aware that there is a limit to how much volume you can handle before gains stall or health suffers, so find your personal threshold.

Dietary protein intake supports but does not independently drive skeletal muscle hypertrophy; its primary role is to amplify the anabolic response to resistance exercise.

Eat enough protein (1.2-1.6 g/kg/day) to support your training, but do not expect it to build muscle on its own. The key to muscle growth is resistance exercise. Protein helps maximize the gains you get from your workouts.

Protein and essential amino acid (EAA) supplementation promotes measurable muscle hypertrophy (via ultrasound/MRI) only when daily intake is below 1.6 g/kg/day or per-meal leucine is below 2–3 g; benefits plateau once these thresholds are met.

If you already eat enough protein (around 1.6g per kg of body weight) or get enough leucine per meal (2-3g), adding more protein powder will not make your muscles grow bigger. Focus on hitting that baseline first; extra protein is wasted for hypertrophy purposes.

Creatine monohydrate (3–5 g/day) increases muscle thickness and cross-sectional area in resistance training interventions lasting 8–12 weeks or more, primarily by enabling higher training volume and quality rather than direct anabolic signaling.

Take 3-5g of creatine monohydrate daily. It won't magically build muscle overnight, but it will help you lift more volume over 8-12 weeks, which leads to actual muscle growth. Don't expect results in the first few weeks.

Female endurance athletes unintentionally underfuel with carbohydrates relative to training volume, creating a cumulative energy deficit, while simultaneously prioritizing protein intake to meet or exceed recommendations.

Female endurance athletes should prioritize carbohydrate intake on training days to match volume, as deficits increase significantly with higher loads. Do not neglect rest days; even low-intensity sessions require adequate fuel to prevent cumulative energy deficits. While protein intake is often correctly prioritized, ensure it does not displace necessary carbohydrates. Address psychological barriers like body image and time constraints by planning simple, accessible carbohydrate sources for all training days, not just hard sessions.

Structured, individualized nutritional interventions significantly improve sport-specific performance and increase energy availability in competitive female athletes compared to generic guidance.

If you are a competitive female athlete, generic advice is likely not enough. You need a personalized plan that targets at least 45 kcal per kg of fat-free mass daily. Focus on consuming 5-8g of carbs and 1.6-2.0g of protein per kg of body weight. Work with a professional to adjust this gradually to avoid psychological resistance, and monitor your energy availability regularly to ensure you are not in a deficit.

Individualized nutritional interventions significantly reduce the prevalence of Female Athlete Triad risk (LEAF-Q ≥ 8) in competitive female athletes.

If you are at risk for the Female Athlete Triad, screening alone is not enough. You need a structured nutritional plan that increases your energy availability to at least 45 kcal/kg of fat-free mass daily. This involves eating enough carbohydrates and protein to support your training load, monitored by a professional to ensure you are not in a deficit.